Search our Database of Scientific Publications and Authors

I’m looking for a

    23417 results match your criteria Drug Eruptions

    1 OF 469

    A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals.
    Ann Transl Med 2017 Oct;5(20):393
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA.
    Background: Identifying the drug(s) responsible for drug-induced chronic eczematous eruptions of aging individuals (CEEA) is a clinical challenge in patients on multiple medications. Reliable in vitro testing methods and biomarkers are needed to identify the causative agent and allow simultaneous assessment of T-cell responses to multiple drugs being taken concurrently. This study examined the feasibility of using in vitro, drug-specific T cell activation responses as a biomarker for drug-induced CEEA. Read More

    Ichthyosiform Pityriasis Rubra Pilaris-Like Eruption Secondary to Ponatinib Therapy: Case Report and Literature Review.
    Drug Saf Case Rep 2017 Nov 14;4(1):19. Epub 2017 Nov 14.
    Department of Dermatology and Cutaneous Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
    Tyrosine kinase inhibitors have revolutionized the chemotherapy arena as targeted therapies for a multitude of malignancies. They are more selective than conventional chemotherapy, and often elicit fewer systemic adverse events, however toxicities still exist. Cutaneous toxicities are common and their management presents a novel challenge to physicians and patients. Read More

    Delayed-type hypersensitivity to oral and parenteral drugs.
    J Dtsch Dermatol Ges 2017 Nov;15(11):1111-1132
    Allergy Unit, Department of Dermatology, Basel University Hospital, Basel, Switzerland.
    Adverse drug reactions of the delayed type rank among the most common dermatoses and are predominantly characterized by exanthematous macular or maculopapular eruptions. However, approximately 2 % of affected individuals develop severe or even life-threatening systemic immune reactions associated with organ involvement, requiring immediate diagnosis and treatment. Numerous drugs are capable of eliciting delayed-type hypersensitivity reactions, with antibiotics, anticonvulsant drugs, and the xanthine oxidase inhibitor allopurinol being the most common. Read More

    A severe case of mango dermatitis.
    J Eur Acad Dermatol Venereol 2017 Oct 28. Epub 2017 Oct 28.
    Department of Dermatology Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15 W7, Kita-ku, Sapporo, 060-8638, Japan.
    A 27-year-old Japanese woman visited our hospital with eruptions on the lips, which had appeared two days after she took acetaminophen. At day 15, her lips were severely swollen with erosions, most of which were covered with dense crusts (Figure 1). Clinically, Stevens-Johnson syndrome due to acetaminophen was suspected. Read More

    [The major SCAR syndromes].
    Rev Med Liege 2017 Oct;72(10):444-447
    Service de Dermatopathologie et Consultant Service de Dermatologie, CHU de Liège, site du Sart Tilman, Liège, Belgique.
    Some drug eruptions are frequent and follow an indolent course, while others prove to be life-threatening. By contrast, SCAR syndromes are serious skin drug reactions that are rare but their vital prognosis is affected. The three distinct entities of importance are the former Lyell's syndrome, now identified as SJS-TEN syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis), the DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), and the AGEP syndrome (acute generalized exanthematous pustulosis). Read More

    Multifocal Fixed Drug Eruption to ceftazidime in a child with cystic fibrosis.
    Pediatr Allergy Immunol 2017 Oct 19. Epub 2017 Oct 19.
    Université Paris Descartes, Paris, France.
    Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by well-delimited pigmented lesions of the skin and/or mucosa [1,2]. FDE is rare and frequently misdiagnosed leading to recurrent eruptions after the offending drug is re-administered [1,2]. The diagnosis hallmark is its recurrence in previously affected sites leading to a residual hyperpigmentation, however some cases without residual pigmentation have been described [2]. Read More

    Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia.
    PLoS Negl Trop Dis 2017 Oct 13;11(10):e0006011. Epub 2017 Oct 13.
    London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom.
    Background: Leprosy reactions are a significant cause of morbidity in leprosy population. Erythema nodosum leprosum (ENL) is an immunological complication affecting approximately 50% of patients with lepromatous leprosy (LL) and 10% of borderline lepromatous (BL) leprosy. ENL is associated with clinical features such as skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. Read More

    Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    J Cutan Pathol 2017 Oct 13. Epub 2017 Oct 13.
    Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
    PD-1 (programmed cell death-1) inhibitors, used to treat metastatic melanoma and other malignancies, are associated with development of immune-related adverse events in the skin. Such reactions include morbilliform eruptions, vitiligo, alopecia areata and bullous pemphigoid. In this report, we describe a patient who developed a lupus-like cutaneous reaction in the setting of pembrolizumab therapy for metastatic melanoma, adding to the spectrum of reactions which may be observed in association with PD-1 inhibitor therapy. Read More

    Fever, rash, and leukopenia in a 32-year-old man · Dx?
    J Fam Pract 2017 Oct;66(10):E7-E10
    Department of Research, Fort Bragg, NC, USA.
    A 32-year-old man was admitted to our hospital with fever, chills, malaise, leukopenia, and a rash. About 3 weeks earlier, he'd had oral maxillofacial surgery and started a 10-day course of prophylactic amoxicillin/clavulanic acid. Fifteen days after the surgery, he developed a fever (temperature, 103° F), chills, arthralgia, myalgia, cough, diarrhea, and malaise. Read More

    T-cell regulation in Erythema Nodosum Leprosum.
    PLoS Negl Trop Dis 2017 Oct 9;11(10):e0006001. Epub 2017 Oct 9.
    London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical Diseases, London, United Kingdom.
    Leprosy is a disease caused by Mycobacterium leprae where the clinical spectrum correlates with the patient immune response. Erythema Nodosum Leprosum (ENL) is an immune-mediated inflammatory complication, which causes significant morbidity in affected leprosy patients. The underlying cause of ENL is not conclusively known. Read More

    Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils.
    Melanoma Res 2017 Dec;27(6):641-644
    aDepartment of Dermatology bDepartment of Pathology, Institute for Clinical Pathology and Medical Research, Westmead Hospital cDepartment of Dermatology, Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
    The introduction of anti-programmed cell death-1 (anti-PD1) monoclonal antibodies has revolutionized the treatment of various advanced malignancies. Despite its efficacy, anti-PD1 therapy is accompanied by a variety of cutaneous adverse events. A 79-year-old man developed erythematous scaly plaques and pustules of the forehead, legs and arms after four cycles of nivolumab infusions every 2 weeks. Read More

    Herpes labialis: An Update.
    Recent Pat Inflamm Allergy Drug Discov 2017 Oct 3. Epub 2017 Oct 3.
    Toronto Dermatology Centre, Toronto, Ontario. Canada.
    Background: Herpes labialis is characterized by recurrent vesicular eruptions primarily on the lips and perioral skin. The condition is contagious, can cause significant discomfort/pain, and can have an adverse effect on quality of life.

    Objective: To update the evaluation and treatment of herpes labialis. Read More

    Etanercept in erythema nodosum leprosum.
    An Bras Dermatol 2017 Jul-Aug;92(4):575-577
    Professor Rubem David Azulay Dermatology Institute, Santa Casa de Misericórdia do Rio de Janeiro (DPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil.
    One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. Read More

    Skin diseases of the male external genitalia in the Tanlangai Hospital in Brazzaville, Congo.
    Med Sante Trop 2017 Aug;27(3):296-300
    CHU Brazzaville, 13 avenue Auxence-IKonga, Brazzaville, Congo.
    To determine the frequency of diseases responsible for skin lesions of the male external genitalia. This descriptive retrospective study examined the medical records of patients older than 14 years treated for genital symptoms as outpatients at the Dermatology Department of Talangaï Hospital in Brazzaville in 2009-2011. Patients' sociodemographic, medical history, clinical, and laboratory data were collected on a standardized individual form. Read More

    New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.
    J Invest Dermatol 2017 Oct;137(10):2047-2049
    Paris, France (retired).
    Sixty years after its original description by Sir Alan Lyell, epidermal necrolysis (from Stevens-Johnson syndrome to toxic epidermal necrolysis) seems finally amenable to a specific treatment in addition to essential symptomatic measures in specialized settings. A recently published systematic review and an article by Gonzales-Herrada et al. strongly suggest that cyclosporine is effective in reducing the risk of death. Read More

    Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity.
    Clin Exp Dermatol 2017 Dec 20;42(8):868-873. Epub 2017 Sep 20.
    Department of Dermatology, Venereology and Andrology , Assiut University, Egypt.
    Background: There is strong evidence that drug-induced cutaneous eruptions have an immunological component. Interleukin (IL)-17, a proinflammatory cytokine that is predominantly produced by T helper 17 cells, has been linked to various autoimmune and inflammatory diseases.

    Aim: To measure serum IL-17 levels in patients with cutaneous drug reactions [erythema multiforme (EM) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)] in order to study the associations between IL-17 and disease severity. Read More

    A Case of Inappropriate Self-Medication Compounded with Prescribing vis-à-vis Dispensing Errors and the Hazardous Consequence.
    Curr Drug Saf 2017 Sep 19. Epub 2017 Sep 19.
    Department of Clinical & Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata. India.
    INTRODUCTION Dispensing error, a type of medication error, is not infrequent but seldom reported. Self-medication behavior appears to be a commonplace. And when it is ignorant it may prove dangerous. Read More

    A cross-sectional survey of voriconazole prescribers: Assessing current practice and knowledge of cutaneous side effects.
    J Am Acad Dermatol 2017 10;77(4):769-770
    Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address:

    Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome.
    Obstet Gynecol 2017 Oct;130(4):881-884
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Naval Medical Center San Diego, San Diego, California.
    Background: Autoimmune progesterone dermatitis is an uncommon disease presenting with cyclical skin eruptions corresponding with the menstrual cycle luteal phase. Because symptoms are precipitated by rising progesterone levels, treatment relies on hormone suppression.

    Case: A 22-year-old nulligravid woman presented with symptoms mistaken for Stevens-Johnson syndrome. Read More

    Olanzapine-induced Skin Eruptions.
    Indian J Psychol Med 2017 Jul-Aug;39(4):537-538
    Department of Psychiatry, National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India.
    Adverse cutaneous reactions are known to occur with psychotropic medications, which may lead to poor drug compliance. As compared to other group of psychotropics, there is relatively scarce literature on olanzapine-induced skin eruptions. We present a case of a 39-year-old man diagnosed with first episode mania and alcohol dependence syndrome who was started on tablet olanzapine which leads to fixed drug eruptions. Read More

    Neosensitization to Multiple Drugs Following Valproate-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome.
    Psychiatry Investig 2017 Jul 11;14(4):518-520. Epub 2017 Jul 11.
    Department of Psychiatry, School of Medicine, Jeju National University, Jeju, Republic of Korea.
    Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is associated with severe skin eruptions, fever, hematological abnormalities, and multi-organ involvement. Although aromatic anticonvulsant drugs have been frequently associated with the manifestation of DRESS syndrome, its induction following treatment with nonaromatic anticonvulsants, such as valproate, has rarely been reported. Moreover, there are limited data regarding the development of neosensitization related to chemically unrelated drugs following an episode of DRESS syndrome. Read More

    Sorafenib stimulates human skin type mast cell degranulation and maturation.
    J Dermatol Sci 2017 Aug 12. Epub 2017 Aug 12.
    Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.
    Background: Sorafenib is a multi-kinase inhibitor for treating advanced hepatocellular and renal cell carcinomas by targeting various types of receptors and signaling molecules, including vascular endothelial growth factor receptors, platelet-derived growth factor receptor, and Raf-1. Sorafenib may cause diverse cutaneous adverse reactions, including hand-foot reaction, facial and scalp eruptions, alopecia and pruritus. However, the mechanism of these adverse effects has not been well-investigated. Read More

    Amoxycillin and clavulanic acid induced Stevens-Johnson syndrome: A case report.
    EXCLI J 2017 18;16:748-751. Epub 2017 May 18.
    Baqai Medical University, Karachi, Pakistan.
    Stevens-Johnson syndrome (SJS) is an immune mediated hypersensitivity reaction. Significant involvement of oral, nasal, eye, vaginal, urethral, GI and lower respiratory tract mucous membrane may develop. It is usually a reaction due to a medication or due to an infection. Read More

    Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
    Am J Surg Pathol 2017 Oct;41(10):1381-1389
    Departments of *Dermatology ‡Pathology §Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center ∥The Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD Departments of †Medicine, Thoracic Oncology Service ¶Pathology #Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY.
    Cutaneous eruptions are among the most common immune-related adverse events (irAEs) associated with anti-programmed cell death protein 1/programmed cell death ligand 1 therapy, and are often clinically and histologically characterized as lichenoid. Nonlichenoid patterns may also occur and are likely to be encountered by surgical pathologists, given the increasing clinical use of these agents. The purpose of this study is to describe the histopathologic features of nonlichenoid cutaneous irAEs from patients receiving anti-programmed cell death protein 1/programmed cell death ligand 1 therapies for a variety of underlying advanced malignancies. Read More


    [DRESS syndrome secondary to antituberculosis drugs: about a case].
    Pan Afr Med J 2017 11;27:37. Epub 2017 May 11.
    Service de Pneumologie, Hôpital Moulay Youssef, CHU, Rabat, Maroc.
    Drug hypersensitivity syndrome or Drug Rash with Eosinophilia and Systemic Symptoms or DRESS syndrome is a severe and potentially life-threatening toxidermia. It should be suspected in patients developing cutaneous reaction following drug intake. We report the case of a 45-year old patient treated for pulmonary tuberculosis (TPM+) who developed DRESS syndrom induced by antibacillaries. Read More

    Three Cases of Autoimmune Progesterone Dermatitis.
    Ann Dermatol 2017 Aug 21;29(4):479-482. Epub 2017 Jun 21.
    Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea.
    Autoimmune progesterone dermatitis is a rare cyclic premenstrual reaction to progesterone produced during the luteal phase of the menstrual cycle. The clinical symptoms of autoimmune progesterone dermatitis overlap with other forms of dermatosis such as erythema multiforme, eczema, fixed drug eruption, urticaria, and angioedema. We experienced 3 cases of autoimmune progesterone dermatitis. Read More

    Prevalence and Clinical Profile of Drug Eruptions among Antiretroviral Therapy-Exposed HIV Infected People in Yaoundé, Cameroon.
    Dermatol Res Pract 2017 28;2017:6216193. Epub 2017 Jun 28.
    Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.
    Background: Prevalence and incidence of drug eruptions vary around the world and are influenced by some key factors including HIV infection.

    Objective: This study aimed to find the peculiarities of drug eruptions in people living with HIV (PLHIV) and on antiretroviral therapy (ART).

    Methods: This was a retrospective cross-sectional study including ART-taking PLHIV, aged 15+ years, followed up between January 2010 and December 2014 at the day-care unit of the Yaoundé Central Hospital, and who presented with drug eruptions after ART initiation. Read More

    Outpatient dermatology consultation impacts the diagnosis and management of pediatric oncology patients: A retrospective study.
    J Am Acad Dermatol 2017 Nov 18;77(5):879-885. Epub 2017 Jul 18.
    Dermatology Program, Boston Children's Hospital, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts. Electronic address:
    Background: The impact of dermatology consultation on the care of children with oncologic conditions is unknown.

    Objective: To review outpatient dermatology visits and the resulting impact on diagnosis and management of pediatric oncology patients.

    Method: Retrospective review of pediatric oncology patients with outpatient dermatology visits at a tertiary care center from 2008 to 2015. Read More

    A Review of the Active Treatments for Toxic Epidermal Necrolysis.
    J Nippon Med Sch 2017 ;84(3):110-117
    Department of Dermatology, Nippon Medical School.
    Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction associated with the separation of skin and mucous membranes at the dermal-epidermal junction. Although it is rare, many treatments have been trialed because of its high mortality rate. Active interventions performed to date include the use of systemic corticosteroids, intravenous immunoglobulins (IVIg), cyclosporine, plasmapheresis, anti-tumor necrosis factor drugs and N-acetylcysteine, but none has been established as the most effective therapy. Read More

    Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum.
    Am J Trop Med Hyg 2017 Jun;96(6):1362-1364
    Department of Leprosy, Shanghai Dermatology Hospital, Shanghai, People's Republic of China.
    AbstractErythema nodosum leprosum (ENL), also known as type II leprosy reaction, is a severe immune-mediated complication of multibacillary leprosy. For ENL, corticosteroids and thalidomide are the mainstays of treatment. Other immunosuppressants, such as clofazimine, cyclosporine, and azathioprine have also been used. Read More

    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Gynecol Oncol 2017 Sep 8;146(3):484-490. Epub 2017 Jul 8.
    Thomas Jefferson University, Philadelphia, PA, USA.
    Objective: Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat versus tamoxifen in patients with biochemical-only recurrence (CA-125 elevation) following complete remission after first-line chemotherapy for advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

    Methods: In this open-label, phase 2 study (NCT01685255), patients were randomised 1:1 to epacadostat 600mg or tamoxifen 20mg twice daily for successive 28-day cycles and stratified by time since completion of first-line chemotherapy to first CA-125 elevation (3 to <12 or ≥12months). Read More

    Allergy Testing in Children With Low-Risk Penicillin Allergy Symptoms.
    Pediatrics 2017 Aug 3;140(2). Epub 2017 Jul 3.
    Pediatric Emergency Medicine.
    Background: Penicillin allergy is commonly reported in the pediatric emergency department (ED). True penicillin allergy is rare, yet the diagnosis results from the denial of first-line antibiotics. We hypothesize that all children presenting to the pediatric ED with symptoms deemed to be low-risk for immunoglobulin E-mediated hypersensitivity will return negative results for true penicillin allergy. Read More

    A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale.
    PLoS Negl Trop Dis 2017 Jul 3;11(7):e0005716. Epub 2017 Jul 3.
    Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
    Objectives: We wished to validate our recently devised 16-item ENLIST ENL Severity Scale, a clinical tool for measuring the severity of the serious leprosy associated complication of erythema nodosum leprosum (ENL). We also wished to assess the responsiveness of the ENLIST ENL Severity Scale in detecting clinical change in patients with ENL.

    Methods: Participants, recruited from seven centres in six leprosy endemic countries, were assessed using the ENLIST ENL Severity Scale by two researchers, one of whom categorised the severity of ENL. Read More

    Meta-analysis of randomized and quasi-randomized clinical trials of topical antibiotics after primary closure for the prevention of surgical-site infection.
    Br J Surg 2017 Aug 28;104(9):1123-1130. Epub 2017 Jun 28.
    Discipline of General Practice, School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
    Background: Surgical-site infections (SSIs) increase patient morbidity and costs. The aim was to identify and synthesize all RCTs evaluating the effect of topical antibiotics on SSI in wounds healing by primary intention.

    Methods: The search included Ovid MEDLINE, Ovid Embase, the Cochrane Wounds Specialized Register, Central Register of Controlled Trials and EBSCO CINAHL from inception to May 2016. Read More

    Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
    Lancet Oncol 2017 Aug 23;18(8):1089-1103. Epub 2017 Jun 23.
    UZ Leuven, Campus Gasthuisberg, Leuven, Belgium.
    Background: Evofosfamide is a hypoxia-activated prodrug of bromo-isophosphoramide mustard. We aimed to assess the benefit of adding evofosfamide to doxorubicin as first-line therapy for advanced soft-tissue sarcomas.

    Methods: We did this international, open-label, randomised, phase 3, multicentre trial (TH CR-406/SARC021) at 81 academic or community investigational sites in 13 countries. Read More

    The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation.
    Allergol Int 2017 Jun 22. Epub 2017 Jun 22.
    Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan. Electronic address:
    Background: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. Read More

    Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Phytother Res 2017 Sep 21;31(9):1323-1329. Epub 2017 Jun 21.
    Pharmaceutical Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
    Hand-foot syndrome (HFS) is a frequent dose-limiting adverse reaction of capecitabine in patient with gastrointestinal cancers. Silymarin is a polyphenolic flavonoid extracted from the Silybum marianum that exhibits strong antioxidant and antiinflammatory activities. In this study, we evaluated silymarin efficacy in prevention of capecitabine-induced HFS in patients with gastrointestinal cancers, as the first human study. Read More

    Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches.
    J Invest Dermatol 2017 Oct 17;137(10):2092-2100. Epub 2017 Jun 17.
    Clinical Pharmacology Unit, Príncipe de Asturias University Hospital, Department of Biomedical Sciences, University of Alcalá, Institute for Health Research IRYCIS, Alcalá de Henares, Madrid, Spain. Electronic address:
    Several immunomodulatory agents are used in the treatment of epidermal necrolysis, but evidence of their efficacy is limited. The Autonomous Community of Madrid has two reference burn units to which all patients with epidermal necrolysis are referred. One burn unit has mostly used cyclosporine (CsA), and the other has used non-CsA therapies (mainly high-dose intravenous immunoglobulin). Read More

    1 OF 469